Stem cell secretome added to stroke care to help thinking recovery
Tests stem cell secretome for thinking problems in people after an ischemic stroke.
Plain-language title generated from the registry record
Registry title: MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke
Key facts
- Where
- Makassar, IndonesiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07731087, who can take part
Where in Indonesia
- Hasanuddin University HospitalMakassar, IndonesiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jumraini Tammasse
- Trial code
- NCT07731087
- Record updated
- 28 July 2026
- Original description
Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.Read full original descriptionShow less
Efficacy of Mesenchymal Stem Cell Secretome Therapy on Cognitive Recovery in Patients With Subacute Ischemic Stroke: A Pilot Randomized Controlled Trial Using qEEG, BDNF, and Interleukin-1β Evaluation
Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.
Inclusion: Age 40 to 75 years; Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging; Stroke onset between 7 days and 3 months before enrollment; Hemodynamically stable; Able to undergo a basic neuropsychological assessment; Mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment; Willing to participate in the study and provide written informed consent.
Exclusion: Concurrent participation in another clinical trial; Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke; History of dementia before stroke or a major neurodegenerative disorder; Active infection, active autoimmune disease, active malignancy, severe renal failure, or severe liver failure; Uncontrolled epilepsy; Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid; Contraindication to any study intervention or study procedure.